Tango Therapeutics, Inc. (TNGX): Total Assets
$398.69M
As of 2025-12-31
$1.07B
As of 2026-06-30
-3.0%
3-year compound annual growth
+14.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $398.69M | +26.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $316.49M | -21.4% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $402.57M | -7.8% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $436.47M | -12.7% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $500.15M | +141.3% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $207.25M | n/a | 2022-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $594.82M | +10.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| Journey Medical Corp (DERM) | 2025-12-31 | $94.59M | +17.9% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $280.73M | -25.5% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $738.36M | -2.9% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $105.01M | -15.4% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.15M | -3.5% |
Compare TNGX, NUVB, FBIO, DERM side by side · Screen every company in Pharmaceutical Preparations ↗